Compare · ABT vs IRON
ABT vs IRON
Side-by-side comparison of Abbott Laboratories (ABT) and Disc Medicine Inc. (IRON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IRON operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 60.3x IRON ($2.91B).
- Over the past year, ABT is down 18.6% and IRON is up 31.7% - IRON leads by 50.3 points.
- IRON has been more active in the news (17 items in the past 4 weeks vs 12 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 20 for IRON).
- Company
- Abbott Laboratories
- Disc Medicine Inc.
- Price
- $100.68+1.91%
- $76.19+3.84%
- Market cap
- $175.37B
- $2.91B
- 1M return
- +11.09%
- +9.11%
- 1Y return
- -18.60%
- +31.75%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 17
- Recent ratings
- 25
- 20
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest IRON
- Chief Executive Officer Quisel John D exercised 33,000 shares at a strike of $10.68 and sold $2,473,780 worth of shares (33,000 units at $74.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 100 shares at a strike of $13.50 and sold $8,250 worth of shares (100 units at $82.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Khara Rahul exercised 2,500 shares at a strike of $14.69 and sold $187,500 worth of shares (2,500 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Yu Jonathan Yen-Wen sold $21,750 worth of shares (300 units at $72.50) as part of a pre-agreed trading plan and exercised 300 shares at a strike of $13.50 (SEC Form 4)
- Disc Medicine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 9,700 shares at a strike of $13.50 and sold $704,795 worth of shares (9,700 units at $72.66) as part of a pre-agreed trading plan (SEC Form 4)
- Disc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Legal Officer Khara Rahul exercised 7,500 shares at a strike of $14.69 and sold $526,661 worth of shares (7,500 units at $70.22) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Quisel John D exercised 34,000 shares at a strike of $9.86 and sold $2,387,296 worth of shares (34,000 units at $70.21) as part of a pre-agreed trading plan (SEC Form 4)